

Review Article

The Basis of Muscle Regeneration

Antonio Musarò^{1,2,3}

¹ *Institute Pasteur Cenci-Bolognetti, DAHFMO-Unit of Histology and Medical Embryology, IIM, Sapienza University of Rome, Via A. Scarpa 16, 00161 Rome, Italy*

² *Center for Life Nano Science@Sapienza, Italian Institute of Technology, Viale Regina Elena 291, 00161 Rome, Italy*

³ *Edith Cowan University, Perth, WA 6027, Australia*

Correspondence should be addressed to Antonio Musarò; antonio.musaro@uniroma1.it

Received 27 March 2014; Revised 28 May 2014; Accepted 18 June 2014; Published 9 July 2014

Academic Editor: Shihuan Kuang

Copyright © 2014 Antonio Musarò. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Muscle regeneration recapitulates many aspects of embryonic myogenesis and is an important homeostatic process of the adult skeletal muscle, which, after development, retains the capacity to regenerate in response to appropriate stimuli, activating the muscle compartment of stem cells, namely, satellite cells, as well as other precursor cells. Moreover, significant evidence suggests that while stem cells represent an important determinant for tissue regeneration, a “qualified” environment is necessary to guarantee and achieve functional results. It is therefore plausible that the loss of control over these cell fate decisions could lead to a pathological transdifferentiation, leading to pathologic defects in the regenerative process. This review provides an overview about the general aspects of muscle development and discusses the cellular and molecular aspects that characterize the five interrelated and time-dependent phases of muscle regeneration, namely, degeneration, inflammation, regeneration, remodeling, and maturation/functional repair.

1. Muscle Regeneration Recapitulates Many Aspects of Development

Regenerative potential, robust in lower vertebrates, is gradually lost in higher vertebrates such as mammals [1–5]. Nevertheless, mammalian tissues, including skeletal muscle, are capable of homeostasis and regeneration, partially recapitulating the embryonic developmental program.

Muscle development and regeneration share common features because the molecular program that underlines prenatal development is reactivated for tissue reconstruction after injury [6–8] (Figure 1). Regenerative medicine has therefore gained important insights through the study of developmental biology.

Skeletal muscles are derived from somites, which receive signals, including Wnts, Sonic hedgehog, BMP-4, insulin-like growth factor-1 (IGF-1), and noggin, from the neighboring tissues that induce primordial muscle precursor cells to be committed in a myogenic fate and to subsequently differentiate into mature muscle [6] (Figure 1(a)).

The molecular basis of muscle development has been successfully studied thanks to the gene targeting approach in which the function of one or more myogenic factors was altered either by producing animals lacking one or more of the factor-encoding genes or by producing transgenic animals in which a specific gene is overexpressed under the control of a muscle-specific promoter.

The paired-domain transcription factors Pax3 and Pax7 act upstream of the primary myogenic basic helix-loop-helix (bHLH) transcription factors (MyoD, Myf5, myogenin, and MRF4), which are responsible for the induction of the myogenic program. Pax3 is expressed in the presomitic mesoderm and early epithelial somites [9, 10]. Gene targeting approaches (Table 1) revealed that Pax3-deficient mice lack the limb and diaphragm muscles [11–13], whereas Pax7, a paralogue of Pax3, is induced during somite maturation, is nonessential for embryonic muscle formation, and plays a critical role for postnatal muscle formation [14–16]. Pax3 plays also a critical role in the migration of muscle precursors, thus regulating the expression of *c-Met* [17], a factor involved




FIGURE 1: Schematic representation of muscle formation during embryonic development and adult regeneration. (a) Developmental myogenesis occurs in two distinct waves of differentiation that are characterized by a specific and sequential pattern of muscle-related gene expression (red arrows). Skeletal muscles are derived from somites, which receive signals from the neighboring tissues, namely, axial structures (neural tube and notochord), dorsal ectoderm, and lateral mesoderm that in turn induce the activation (blue arrows) of muscle regulatory factors. Shh (from the notochord) and Wnt1/3 and Wnt11 and IGFs (from dorsal neural tube) signaling have been demonstrated to regulate the expression of Myf5. Pax3 and Myf5 independently regulate MyoD expression, whereas Myf5 regulates the transient expression of MRF4. Myf5 and MyoD independently activate the expression of Myogenin, which promotes the expression of Myosin. (b) Illustration of the lineage progression of adult myogenesis during muscle regeneration, which recapitulates many of the cellular and molecular aspects of muscle development illustrated in panel (a). Environmental cues (Notch, IGF-1, Wnt, etc.) influence the activity of satellite cells (green arrows). Notch and IGF-1 signaling stimulate the proliferation of satellite cells, whereas Wnt signaling is involved in the transition from proliferation to the differentiation phase of myoblasts. Notch signaling is also necessary for the maintenance of the quiescent state of satellite cells. Depending on MyoD activity, satellite cells can follow one of two fates: they may maintain Myf5 expression while downregulating MyoD and self-renewing; alternatively, they maintain MyoD expression and differentiate. Quiescent satellite cells express Pax3 and Pax7. Pax7 regulates MyoD and Myf5 expression (blue arrows). Myf5 regulates the expression of MyoD, which in turn promotes the expression of myogenin and MRF4 (blue arrows). Myogenin promotes the expression of Myosin (blue arrows).

in the delamination and migration of limb-muscle precursors [18].

The four myogenic regulatory factors (MRFs) MyoD, Myf5, myogenin, and MRF4 orchestrate an entire program of muscle-specific gene expression when ectopically expressed in nonmuscle cell types [19]. Functionally, the myogenic bHLH factors act as heterodimers, interacting with ubiquitous bHLH proteins, known as E-proteins, and with other myogenic transcription factors, such as the members of MEF family, which act in a combinatorial fashion to activate muscle gene expression (reviewed in [20]).

Myf5 is activated first in the medial and epaxial somite progenitors, which give rise to the deep back muscles; Myf5 is later activated in the lateral hypaxial somite cell progenitors, which give rise to the limb, diaphragm, and body wall muscles [21–24]. Muscle progenitor lineages that give rise to hypaxial and limb muscles also activate the expression of MyoD [25].

Gene targeting experiments (summarized in Table 1 and reviewed in [19]) have revealed the specific contribution of MRFs to muscle development and the establishment of skeletal muscle cell commitment and differentiation. The activation of MyoD/Myf5 represents the key step for the commitment of multipotential somite cells to the myogenic lineage; the disruption of both genes in the double knockout MyoD-null/Myf5-null mouse results in the absence of skeletal myoblasts (Table 1) [19, 26]. Moreover, these studies indicate that Myf5 has regulatory functions in muscle progenitor specification, and MyoD has subsequent functions in muscle differentiation (Figure 1(a)). In contrast, myogenin appears to function downstream of Myf5 and MyoD and plays a critical role in the terminal differentiation of myoblasts (Figure 1(a)); however, myogenin is also dispensable for establishing the myogenic lineage (Table 1) [19, 27, 28].

The specific role of MRF4 during myogenesis is somewhat more complex; however, its temporal expression pattern

TABLE 1: Gene-targeting of factors involved in muscle development.

Gene knockout	Phenotype	References
Pax3	Absence of the limb and diaphragm muscles	[11–13]
Pax7	(i) Normal muscle development (ii) Satellite cells are progressively lost postnatally because of apoptosis accompanied by cell cycle defects	[15, 16, 140]
MyoD	(i) Viable without obvious defects (ii) Increased expression of myf-5 (iii) Normal expression of myogenin (iv) Impaired regeneration	[182–184]
Myf5	(i) Muscle develops relatively normally (ii) Normal expression of myogenin (iii) Hypertrophy and fibrosis in adult life	[21, 29, 185–187]
Myogenin	(i) Die perinatally (ii) Prevents muscle differentiation (despite the continued expression of MyoD) (iii) Reduced muscle	[19, 27, 28, 188, 189]
MRF4	(i) Variable viability dependent on targeting construct (ii) No obvious muscle defects	[19, 20, 29, 190, 191]
MyoD and Myf5	(i) Die perinatally (ii) Absence of skeletal muscle cells (iii) Absence of myogenin (iv) No markers of differentiation	[19, 26]

suggests potential roles in both muscle determination and terminal differentiation [19, 20, 29]. The muscles of adult mice express high levels of MRF4, whereas myogenin, MyoD, and Myf5 expression are reduced during postnatal life [30]. Interestingly, the expression of MyoD and myogenin mRNA and protein are reactivated in the skeletal muscles of aged animals [30, 31], and their expression pattern is similar to that recorded in young adult denervated muscles, suggesting that muscle aging could involve the denervation of myofibers.

The myogenic program, as well as muscle regeneration, is also regulated at epigenetic level. In proliferating myoblasts, the ability of the MRFs to activate the differentiation program is countered by the association of muscle regulatory regions with histone deacetylases (HDACs) and corepressor complexes, including YY1 and polycomb proteins, which preclude premature muscle-gene expression by promoting histone modifications [32]. The class II histone deacetylases (HDAC4 and HDAC5) interact with MEF2 proteins and repress the activation of transcription from promoters containing MEF2 sites [33]. The class I histone deacetylase HDAC1 associates directly with MyoD, is capable of deacetylating MyoD *in vitro*, and inhibits the ability of PCAF to enhance MyoD-dependent transcription in cell culture experiments [20]. In the adult, class IIa histone deacetylases together with PGC-1 α (peroxisome proliferator-activated receptor gamma, coactivator 1 alpha) and NFAT (nuclear factor of activated T-cells) control the slow myofiber gene expression program [34].

In particular, signaling by calcium/calmodulin-dependent protein kinase (CaMK) and protein kinase D (PKD) induces the phosphorylation of class IIa HDACs, which creates docking sites for the 14-3-3 chaperone protein, resulting in nuclear export with the consequent activation of slow myofiber genes [34]. Additionally, HDAC9 has been shown to modulate the response of skeletal muscle to motor innervations [34].

Recent studies have also revealed that myogenic transcription factors control the expression of a group of microRNAs (miRNA or miR), which act through multiple mechanisms to modulate muscle development and function [35–37].

miRNAs are endogenous and ~22 nucleotides long and inhibit translation or promote mRNA degradation by annealing to complementary sequences in the 3' untranslated regions (UTRs) of specific target mRNAs [38]. MicroRNA expression profiles are highly dynamic during embryonic development and in adulthood. The misexpression of microRNAs can perturb embryogenesis, organogenesis, tissue homeostasis, and the cell cycle [39].

Interestingly, many miRNAs are expressed in a tissue-specific manner, and several miRNAs, such as miR-1, miR-133, miR-214, miR-181, and miR-206, are specifically expressed in skeletal muscles [35–37]. miR-214 is expressed during somitogenesis and modulates the response of muscle progenitors to Hedgehog signaling [35]. miR-1 and miR-133 modulate muscle growth and differentiation by regulating serum response




FIGURE 2: Schematic model outlining the different phases of muscle regeneration. Muscle regeneration occurs in five interrelated and time-dependent phases (text in blue). The necrosis of muscle fibers activates a transient muscle inflammation, which is necessary for the removal of necrotic cellular debris. Inflammation is followed by a regeneration phase that is characterized by the activation of stem cell populations (satellite cells and other nonmuscle stem cells), which replace damaged myofibers. The fourth phase involves the remodeling of extracellular matrix and angiogenesis. The muscle regeneration is completed by the reinnervation of regenerating fibers.

factor (SRF) and MEF2 activity and thus have distinct roles in modulating skeletal muscle proliferation and differentiation in cultured myoblasts *in vitro* [35–37]. miR-133 enhances myoblast proliferation by repressing SRF [36, 40]. In contrast, miR-1 promotes myogenesis by targeting HDAC4, a transcriptional repressor of muscle gene expression [36, 40]. Similar to miR-1, miR-206 also promotes skeletal muscle differentiation through the negative regulation of DNA polymerase α (polA1) translation, repression of cyclin-dependent kinase 2 (Cdk2) activity and downregulation of connexin 43 [35]. miR-181 is upregulated upon differentiation and stimulates muscle growth [35]. The activity and expression pattern of different myo-miR suggests that miRNAs can play roles in establishing a differentiated phenotype and suggests a potential role for miRNAs in skeletal muscle regeneration and diseases.

2. Muscle Regeneration: The Phase of Necrosis and Inflammatory Response

Notably, most of the factors involved in muscle development are activated during muscle regeneration (Figure 1(b)) [7, 8]. Muscle regeneration occurs in five interrelated and time-dependent phases, namely, degeneration (necrosis), inflammation, regeneration, remodeling, and maturation/functional repair (Figure 2). Although the phases of muscle regeneration are similar in different organisms (e.g., mouse, rat, and human) and after different types of damage/trauma, the kinetics and amplitude of each phase are different in each organism and may depend on the extent of damage and the damage model used.

One of the most frequently used and the easiest and most reproducible methods to induce muscle regeneration is based

on cardiotoxin (CTX) injection, a peptide that is isolated from snake venoms and acts as protein kinase C-specific inhibitor. CTX produces a local myonecrosis and stimulates muscle regeneration [8, 41–44].

Necrosis involves the influx of calcium ions, the loss of the plasmalemma, myonuclear, contractile material, and cellular organelles dissolution, leading to amorphous debris. Necrotic fibers appear pale and enlarged with altered internal architecture and with the presence of internal nuclei, which may reflect invasion by macrophages. Evans Blue Dye is an *in vivo* evaluable marker of necrotic myofibers and can be administered as an intravital dye into the tail vein of mice and identified macroscopically by the striking blue colour within tissue, or observed by red autofluorescence in tissue sections examined by fluorescence microscopy [45].

Necrotic cell death stimulates a host inflammatory response (Figure 2).

The inflammatory response of injured skeletal muscle plays an important and critical role in muscle homeostasis and regeneration and involves the recruitment of specific myeloid cell populations within the injured area [46–50].

Neutrophils represent the first inflammatory myeloid cells that invade the site of muscle injury; the number of neutrophils usually drops 24 hours after damage; neutrophils are normally no longer detectable after 36–48 hours after injury [51, 52] (Figures 2 and 3).

Neutrophils enter into damaged tissue by interacting with adhesion molecules of vascular endothelial cells [53–57], a process that is mediated by the interaction of a $\beta 2$ integrin on neutrophils with vascular ligands such as intracellular adhesion molecule-1 [53, 55].

The phagocytic activity of neutrophils involves the release of high concentrations of free radicals and proteases, as well as the secretion of proinflammatory cytokines that stimulate




FIGURE 3: Schematic diagram of time-dependent cellular response following cardiotoxin (CTX) injection. The relevant biological responses, activated after CTX injection, are indicated. A few hours after cardiotoxin treatment, neutrophils infiltrate between the necrotic fibers, and, by 24 hr after injection, the inflammatory response is characterized by neutrophil and macrophage infiltration. At this stage, the phagocytosis of necrotic myofibers is very active. During the second day after treatment, spindle-shaped mononucleated cells mixed with necrotic debris, leukocytes, and different classes of macrophages appear. New myofibers appear during the following day, and, by 7–10 days after injection, the overall architecture of the muscle is restored, although most regenerated myofibers are smaller and display centrally located myonuclei. The progressive maturation of regenerating myofibers occurs by 15 days.

the homing of other inflammatory cell populations, namely, monocytes and macrophages [49] (Figure 2).

The production of soluble interleukin-6 receptor (sIL-6R) by neutrophils regulates the change from a neutrophilic to a mononuclear population.

Macrophages rapidly increase within 24 hours after injury (Figure 3). They are the predominant inflammatory cell type within the injured area and are detectable at the levels of the perimysium and epimysium. Macrophages remove tissue debris and activate stem cell populations [58–63] (Figure 2). In a pioneering study, McLennan [61] described different populations of macrophages with potentially differing activities: ED2+ and ED3+ resident macrophages, which presumably do not possess phagocytic activity, are abundant in uninjured muscles but are not present within the degenerating fibers, while ED1+ cells are rarely observed within the undamaged regions of the muscles but are abundant in the perimysium between arterioles and degenerating fibers. Recent evidence supports a model according to which the tissue macrophage subtype specification is distinct from that of circulating monocytes [64]. Circulating monocytes can be classified into at least two populations, the $CX_3CR1^{\text{lo}}CCR2^+Gr1^+$ “inflammatory” subset monocyte, which is actively recruited to inflamed tissues, and $CX_3CR1^{\text{hi}}CCR2^-Gr1^-$, which display an anti-inflammatory function and invade the damaged tissue in a second wave of infiltration to support tissue repair [65, 66]. Other evidence supports the hypothesis that the inflammatory monocytes are actually the only monocyte population that is recruited in injured skeletal muscle; then they switch to anti-inflammatory macrophages to support myogenesis [59, 67]. M1 and M2 nomenclature is usually used to refer to the two extremes of a spectrum of possible forms of macrophage activation. In particular, it has been proposed that macrophages develop into either type 1 inflammatory (M1) or type 2 anti-inflammatory (M2) subsets and that macrophages sequentially change their functional phenotype in response to

changes in microenvironmental influences (Table 2) [68]. The M1 phenotype expresses CD68 and is typically interleukin-(IL)-12^{high} and IL-10^{low} [69–71], whereas M2 macrophages express CD163 and are typically IL-10^{high} and IL-12^{low} [58, 69, 72] (Table 2). M1 macrophages are activated by the T-helper (Th) 1 cytokines interferon-gamma (IFN- γ), tumor necrosis factor-alpha (TNF- α), lipopolysaccharide (LPS), IL-1, and IL-6 [69] (Table 2). The M2 population is divided into three possible subtypes: M2a, M2b, and M2c, each with diverse physiological roles (Table 2). M2a are induced by exposure to IL-4 and IL-13; M2b are induced by combined exposure to immune complexes and toll-like receptors (TLR) or IL-1R agonists; M2c macrophages are induced via IL-10 [69] (Table 2). M2a and M2b macrophages exert immunoregulatory functions and drive type II responses, whereas M2c are more related to the suppression of immune responses and tissue remodeling [69] (Table 2).

What are the factors/signaling processes that mediate macrophage polarization?

It has been demonstrated that IL-10 plays a central role in regulating the switch of muscle macrophages from a M1 to M2 phenotype in injured muscle in vivo, and this transition is necessary for proper and efficient muscle growth and regeneration [73]. The ablation of IL-10 amplified the inflammatory response, causing increases in IL-6 and CCL2 while preventing the switch to CD163-positive and arginase-1-positive M2 macrophages. This resulted in the accumulation of muscle fiber damage and altered muscle regeneration and growth [73].

Macrophage polarization is mediated by STAT protein activity. STAT1 is an essential mediator of M1 macrophage polarization in the presence of IFN- γ , whereas STAT6, which is activated by IL-4 and/or IL-13, is required to drive M2 macrophage activation [74]. The mutual exclusivity of these signaling pathways could be a crucial factor in M1 versus M2 polarization and represents a potential target for

TABLE 2: Characteristics of macrophage subtypes.

Subset of macrophages	Factors driving macrophages polarization	Molecules expressed by polarized macrophages	Functional properties of polarized macrophages
M1	IFN- γ + LPS, TNF α	TLR2, TLR4, CD16, CD32, CD64, CD80, CD86, IL-12, IL-23, TNF- α , IL-1, IL-6, Type I IFN, IL-1RI, IL-15Ra, IL-7R, CXCL9, CXCL10, CXCL11, CCL2, CCL3, CCL4, CCL5, CXCL8, CXCL16, CCR7, COX2, iNOS, and miR-26-2	Proinflammatory properties, phagocytosis, and cytotoxic and antitumoral properties
M2a	IL-4, IL-13	CD163, CD23, CD302, CD209, IL-10 Decoy IL-1RII, CCL17, CCL22, CCL24, CXCR1, CXCR2, miR-193b, and miR-222	Anti-inflammatory properties and immunoregulatory functions drive type II responses
M2b	IC + TLR	CD163, IL-10, CCL1, miR-27a, miR-222, miR29b-1, and miR-132	Anti-inflammatory properties and immunoregulatory functions drive type II responses
M2c	IL-10	CD163, scavenger receptor A and B, CD14, CCR2, CCL16, CCL18, CXCL13, CD204, and CD206	Suppression of immune responses and tissue remodeling

IC: immune complexes; IFN-g: interferon-g; LPS: lipopolysaccharide; TLR: toll-like receptor; COX2: cyclooxygenase 2; TNF α : tumour necrosis factor; iNOS: inducible nitric oxide synthase; Interleukin-: IL-.

the modulation of macrophage polarization for therapeutic purposes.

In a recent work, Mounier et al. [75] documented the critical role of a master regulator of energy homeostasis, namely, AMPK α 1, in macrophage skewing. AMPK α 1 is the only catalytic subunit of AMPK that is expressed in macrophages [76]. Using various genetic mouse models, the authors reported that the ablation of AMPK α 1 expression resulted in (i) the accumulation of necrotic tissue after damage, (ii) a delay in the disappearance of phagocytosed myofibers, (iii) a deficit in the acquisition of the M2 macrophage phenotype, and (iv) impaired skeletal muscle regeneration [75].

Gene knockout experiments were supported by the pharmacological inhibition of AMPK activity: wild-type macrophages treated with an inhibitor of calcium/calmodulin-dependent protein kinase 2 (CAMKK2), which is an upstream activator of AMPK, also failed to switch to an M2 phenotype following the phagocytosis of apoptotic myoblasts.

Thus, AMPK α 1 is crucial for M1 to M2 macrophage skewing, which is necessary for a proper regenerative process [75–78].

Epigenetic mechanisms are also implicated in macrophage polarization [79], and the role of miRNAs in regulating macrophage activation in response to different environmental cues has been defined. It has been reported that M2 macrophages express greater levels of miR-125a-5p than do M1 macrophages [80]. The overexpression of miR-125a-5p diminished the M1 phenotype expression induced by LPS but promoted the M2 marker expression induced by IL-4 [77]. In contrast, the knockdown of miR-125a-5p promoted M1 polarization, while diminished IL-4 induced M2 marker expression [80]. Moreover, miRNA let-7c is expressed at a higher level in M2 than in M1 macrophages [81].

In the context of “functional” regeneration, M2 macrophages appear soon after M1 macrophages and play

an important role in deactivating M1 macrophages [59]. Under pathologic conditions, it is possible that the M1 macrophage influx is accompanied by the contemporaneous invasion of M2a macrophages. This is the case for muscular dystrophy [82, 83], in which the simultaneous recruitment of M1 and M2a macrophages may reduce the muscle damage caused by M1 macrophages. Moreover, Villalta and coworkers [83] reported that the selective deactivation of the M1 phenotype in a dystrophic mdx animal model was associated with reduced expressions of IL-6, monocyte chemoattractant protein-1 (MCP-1), interferon-gamma-inducible 10-kDa protein (IP-10), and iNOS, which mediate the cytotoxicity of M1 macrophage population [83]. In contrast, arginase-expressing M2a macrophages can reduce muscle cell damage caused by M1 macrophages in mdx dystrophy, improving satellite cell proliferation [83].

Thus, the inflammatory response is a coordinate process that must be finely regulated to obtain an efficient regenerative process, and the perturbed spatial distribution of inflammatory cells, altered identity of the inflammatory infiltrate (cell type and magnitude of influx), and disrupted temporal sequence result in a persistent rather than resolved inflammatory phase [84].

3. The Phase of Regeneration, Remodeling, and Maturation

The regenerative capacity of the skeletal muscle is guaranteed by an intrinsic mechanism that restores the injured contractile apparatus.

The dominant role in muscle regeneration is played by the muscle stem cells known as satellite cells [85, 86], which reside between the basal lamina and sarcolemma of myofibers and were described as “dormant myoblasts that failed to




FIGURE 4: The molecular signature of satellite cells. Satellite cells express specific markers during the different stages of muscle regeneration. The text in blue indicates the molecular markers activated by satellite cells; the text in green indicates the molecular markers that are upregulated by satellite cells; the text in red indicates the markers that are downregulated by satellite cells in a specific stage of differentiation.

fuse with other myoblasts and are ready to recapitulate the embryonic development of the skeletal muscle fibers when the main multinucleate cell is damaged” [85]. Thus, satellite cells are mitotically quiescent until required for growth or repair.

Satellite cells are activated in response to both physiological stimuli (such as exercise) and pathological conditions (such as injury and degenerative diseases) to generate a committed population of myoblasts that can either fuse with existing myofibers, repairing damaged muscle fibers, or alternatively fuse to each other to form new myofibers [87] (Figure 4). A small minority does not differentiate but instead reenters quiescence to maintain the stem cell pool [88].

The discovery of molecular markers selectively expressed by satellite cells but not by muscle fibers has contributed to the characterization of these markers (Figure 4). It has been reported that c-Met [89], M-cadherin [90], FoxK [91], Pax7 [15], NCAM [92], syndecan 3 and 4 [93], CD34 [94], caveolin-1 [95], Sox 8 [96], Sox 15 [97], VCAM-1 [98], integrin α 7 [99], β 1 integrin [100], calcitonin receptor (CTR) [101], lamin A/C [99], emerin [99], Hey1, and Heyl [102] are expressed by quiescent satellite cells, and their expression increases once satellite cells are activated and proliferated [86] (Figure 4). Pax3, the paralog of Pax7, is also expressed in quiescent muscle satellite cells in a subset of muscles. Pax3 plays an

important role in regulating the entry of satellite cells into the myogenic program [103, 104].

The relevant markers of proliferating satellite cells, which are silent in quiescent satellite cells, are desmin, Myf5, MyoD, and PCNA [86, 105, 106] (Figure 4). In particular, a Myf5 promoter activity has been demonstrated in resident satellite cells using the knock-in Myf5nLacZ^{Pos} [94, 107, 108]. However, Myf5 protein expression has not been detected in quiescent satellite cells, but it is expressed in proliferating progeny and its expression decreases when satellite cells differentiate; thus, the Myf5 protein is not detected upon differentiation and fusion into myotubes [101, 109]. Once activated, satellite cell progeny can follow one of two fates depending on MyoD activity. Satellite cells may downregulate MyoD and self-renew, guaranteeing the maintenance of a pool of quiescent Pax7^{Pos} satellite cells. Alternatively, satellite cells maintain MyoD expression but downregulate Pax7 and activate myogenin expression, thus committing to differentiation [110–113] (Figure 2).

The transition from cell proliferation to differentiation involves the downregulation of proliferative-associated genes and cell-cycle withdrawal [107, 109, 114] (Figure 4).

A key role in asymmetrically segregated transit-amplifying cells is played by Notch, Numb, and Wnt. Numb has been demonstrated to promote myogenic differentiation,

thus inhibiting Notch signaling in one daughter satellite cell [115–120]. A recent work revealed that Numb is also necessary for satellite cell-mediated repair because Numb-deficient satellite cells have an unexpected proliferation defect due to an upregulation of myostatin [121].

The onset of differentiation is due to a transition from Notch signaling to Wnt signaling in myogenic progenitors, and this crosstalk occurs via GSK3 β , which is maintained in an active form by Notch but is inhibited by Wnt [122, 123].

Recent studies have uncovered a novel function for Notch signaling in the regulation of cellular quiescence in adult muscle stem cells [118?]. Notch signaling has been demonstrated to be necessary for the maintenance of the quiescent state and for muscle stem cell homeostasis, and it has been suggested that Hes1, Hey1, and HeyL, which are downstream targets of Notch signaling, are good candidates to mediate the Notch regulation of satellite cell maintenance by preventing their differentiation [118?]. It is likely that Notch signaling can act either to promote or to block the cell cycle progression depending on the cellular context. This divergent behavior of Notch activity could depend on the level of Notch activity and/or the activation of other pathways that may interact with and influence Notch signaling.

The transition from proliferation to differentiation results in the activation of specific markers (Figure 4), including myogenin, neonatal isoform of myosin heavy chain (MyHC), slow-twitch skeletal muscle troponin T (Tnnt1), cardiac and slow-twitch skeletal muscle Ca²⁺-ATPase (Atp2a2), insulin-like growth factor-2 (IGF-2), fibroblast growth factor receptor 4 (Fgfr4), nicotinic cholinergic receptor alpha polypeptide 1 (Chrna1), and cardiac/slow-twitch skeletal muscle troponin C (Tnnc) [124].

Specific epigenetic events are also required to establish and maintain the myogenic identity in quiescent satellite cells and to enable the proper response to external cues once muscle stem cells are activated and exposed to the regenerative environment (for review [125]). miR-1 and miR-206 facilitate satellite cell differentiation by restricting their proliferative potential [40]. In particular, miR-206 is restricted to differentiating satellite cells and plays the crucial role of repressing Pax7 [126]. More recently, quiescence-specific miRNAs have been identified in the satellite-cell lineage [127]. Among these, miRNA-489 is highly expressed in quiescent satellite cells and is quickly downregulated during satellite cell activation, whereas satellite cells that lack a functional miRNA pathway spontaneously exit quiescence and enter the cell cycle [127].

Satellite cells are generally considered to be a homogeneous population of committed muscle progenitors [128]. However, several studies have raised the possibility that satellite cells are a heterogeneous mixture of two populations, namely, slow-cycling stem cells and fast-cycling committed myogenic progenitors [113, 129–132], and have indicated that the asymmetric division in the satellite cell niche is the mechanism for generating these two different populations [116]. In particular, it has been demonstrated that Pax7-positive satellite cells that lack Myf5 expression have a “stem-like” phenotype within the satellite cell population, whereas

Pax7-positive satellite cells expressing Myf5 were more frequently committed to a muscle fate [116].

More recently, satellite cells have been demonstrated to divide predominantly via asymmetric chromatid segregation, generating a daughter cell that carries the mother DNA and retains stem cell properties and a daughter cell that inherits the newly synthesized DNA and acquires the myocyte lineage [133]. Using transgenic approaches, Rocheteau et al. [133] identified two different populations of Pax7-positive cells, Pax7^{Hi} and Pax7^{Lo}. Pax7^{Hi} quiescent stem cells constitute a metabolically low “dormant” subpopulation and selectively segregate old DNA strands to the renewing stem cell. With asymmetric chromatid segregation, a dividing mother stem cell synthesizes new DNA during S-phase and generates two daughter stem cells, one carrying only the mother DNA, which is the true stem cell, and the other only the newly-synthesized DNA [134].

Different studies also clarified the controversial observations about the dominant role of Pax3 or Pax7 on satellite cell specification and activation [15, 104, 135, 136]. It has become clear that satellite cells are present, although in reduced numbers, in the absence of Pax7 and that these cells retain their myogenic potential [135], suggesting that Pax3 alone is responsible for their initial presence in the Pax7 mutant after birth. However, in the absence of Pax7, satellite cells are progressively lost postnatally because of apoptosis accompanied by cell cycle defects [104], suggesting that Pax7 plays an antiapoptotic function in activated satellite cells.

Recent studies using inducible Cre/loxP conditional gene inactivation have reported contradictory evidence regarding the role of Pax7 in satellite cells and muscle regeneration. It has been demonstrated that Pax7 is only required up to the neonatal period (between 7 and 11 days postnatally) [136]. Surprisingly, when Pax7 was inactivated in adult mice, mutant satellite cells were not compromised in muscle regeneration; they could proliferate and reoccupy the sublaminar satellite niche and were able to support further regenerative processes [136]. This normal regenerative capacity of conditional Pax7 mutants sharply contrasts with the severe defects observed in Pax7 knockout mice [15, 135, 136] and indicates the possibility of adult-specific compensation by Pax3. Surprisingly, muscle regeneration was not impaired in Pax3/Pax7 doubly inactivated muscles, suggesting that, contrary to their essential roles in embryonic myogenesis, neither Pax3 nor Pax7 is required during adult muscle regeneration [136]. Conversely, recent works by von Maltzahn et al. [137] and by Günther et al. [134] demonstrated that Pax7 is an absolute requirement for satellite cell function in adult skeletal muscle because Pax7 null satellite cells and myoblasts exhibit cell cycle arrest and the dysregulation of myogenic regulatory factors.

There could be various reasons for these discrepant results: (a) in the Lepper et al. study [136], muscle regeneration was assayed within 10 days after injury, thus addressing the short-term effects of Pax7 inactivation. (b) It has been observed that the ablation of Pax7, reported by Lepper et al. [136], is incomplete because the Pax7^{loxP-Le} allele showed

remaining transcriptional activity, which could confer a residual biological activity [134].

In conclusion, muscle regeneration was severely impaired when Pax7 expression was ablated in most satellite cells, causing an alteration in the maintenance of the satellite cell pool, which was most likely due to premature differentiation at the expense of proliferation [134].

It has been suggested that other “nonmuscle” stem cell populations can participate in muscle regeneration and in some way contribute to maintain the pool of satellite cells (reviewed by Messina et al. [138]). These stem cell populations could either reside within muscle or be recruited via the circulation in response to homing signals emanating from the injured skeletal muscle. These populations include endothelial-associated cells [139], interstitial cells [140–145], and bone marrow-derived side population cells [146, 147].

Two recent reports have described the identification of muscle-derived interstitial cells, which are mesenchymal progenitors [148]. These interstitial cells are referred to as fibroadipocyte progenitors (FAPs) based on their high Scd expression [149] or PDGF receptor alpha (PDGF-R-alpha) expression [150], respectively.

In resting muscles, the interaction with intact myofibers has been demonstrated to prevent the conversion of FAP into fibroadipocytes [149]. However, under physiologic regenerative stimuli, paracrine factors are produced that promote satellite cell-mediated regeneration [151]. In contrast, in degenerating muscles, such as dystrophic muscles at advanced stages of disease, these cells turn into fibroadipocytes, which mediate fat deposition and fibrosis [149], contributing to the exacerbation of the dystrophic hostile microenvironment.

This suggests that a qualitative microenvironment is necessary to physiologically instruct stem cells and that an altered niche negatively influences stem cell commitment and differentiation.

The remodeling of connective tissue and angiogenesis defines the fourth stage of the regenerative process [44, 150, 152, 153] (Figure 2). This stage is characterized by the activation of the extracellular matrix (ECM), resulting in the overproduction of several types of collagens, fibronectin, elastin, proteoglycans, and laminin [150], which serve to stabilize the tissue, to act as a scaffold for the new fibers, and to guide the formation of neuromuscular junctions (NMJs) [154].

Although the entire process of fibrosis formation is poorly understood, transforming growth factor- β 1 (TGF- β 1) has been identified to be a key factor in activating the physiological fibrosis cascade in injured skeletal muscle [155]. This fibrotic response is initially beneficial because it is quick, adds support for strength, and helps protect the injury site. However, the overproduction of collagens within the injured area often leads to heavy scarring and the loss of muscular function.

The reparative process is completed when injured myofibers rescue their functional performance and contractile apparatus [44] (Figure 2). Thus, the regeneration of damaged or diseased muscles is only beneficial if the regenerated muscles become effectively innervated. Within two weeks of

damage, newly formed NMJs between the surviving axons and the regenerated muscle fibers can be identified. Of note, while the initial phases of muscle regeneration do not necessarily depend on neural influence, the subsequent growth and maturation of regenerating muscle fibers require the presence of the nerve because nerve activity can directly influence protein turnover and gene expression within multinucleated regenerating myotubes and indirectly influence the proliferation and differentiation of satellite cells [156–158]. The role of the nerve in controlling the maturation of regenerating innervated myofibers can be monitored by analyzing the expression of different myosin heavy chain (MyHC) isoforms. Regenerating muscle fibers initially express developmental MyHC forms, such as embryonic and neonatal MyHCs (Figure 3), and later on adult fast and slow MyHC forms [159–161].

4. Muscle Regeneration Is Affected in Aging and Muscle Diseases

Muscle regeneration is affected in several pathologic conditions.

The functional performance of skeletal muscle tissues declines during postnatal life and is compromised in different diseases due to an alteration in muscle fiber composition, atrophy, and an overall decrease in muscle integrity as fibrotic invasions replace functional contractile tissue [162–165]. Despite no conclusive evidence, it is becoming more widely accepted that the chronic nature of the inflammatory response to tissue damage is a key driver of the fibrotic response in diverse organs and tissues. Thus, chronic inflammatory response and fibrosis create a hostile microenvironment that inhibits the physiological activity of stem cells and could interfere with muscle regeneration.

The potential critical role of the microenvironment on stem cell biology and therapy is underlined by recent studies, including those by us.

Heterochronic experiments have demonstrated that old muscle successfully regenerates when transplanted in a young animal, whereas the regeneration of young muscle transplanted in an old host is impaired [166, 167]. This hypothesis has been clearly validated in parabiotic experiments, demonstrating the rejuvenation of aged progenitor cells by exposure to a young systemic environment [168]. These results emphasize the importance of the environment, which is created by circulating factors and by the local secretome of factors secreted by satellite cells, the newly differentiating fibers, as well as by the inflammatory cells [169, 170].

In a recent work, we demonstrated that satellite cells display a delayed response to activating stimuli and show a reduced proliferative response to their environment when this environment was suboptimal [171]. We demonstrated that aged satellite cells did not display major defects in the propensity to fuse when differentiating under standard conditions, namely, in DMEM supplemented with 5% horse serum [171]. In contrast, muscle differentiation was dramatically reduced when old satellite cells were cultured in autologous serum (isochronic culture conditions), whereas

the differentiative capacity of aged satellite cells was rescued when differentiated in heterologous/heterochronic serum (from young donors) [171].

Paliwal and coworkers [172] reported that age-dependent increases in the levels of osteopontin (OPN) inhibit skeletal muscle regeneration. The transient upregulation of OPN after muscle injury has been demonstrated to play a positive role in overall regeneration [173]; however, in cultured myoblasts, OPN has been shown to inhibit cell migration and differentiation [174] as well as muscle regeneration in mdx mice [175]. Paliwal et al. [172] demonstrated that OPN is elevated in the blood serum of old mice and only if these animals are injured, suggesting that this cytokine can potentially deregulate regenerative responses and can represent a systemic molecular marker of altered muscle regeneration. Notably, the regeneration of old injured muscle was significantly enhanced by the neutralization of OPN, and young intramuscular CD11b⁺ macrophage injection also enhanced the myogenic responses of old satellite cells in the presence of old myofibers and old serum, suggesting that the secretome of young inflammatory cells is capable of negating the inhibitory influence of old stem cell niches [172].

In another work, by analyzing both muscle morphology and function in aged and transgenic dystrophic animal models, we observed a significant decrease in myonecrosis and a reduction in fibrosis in mice overexpressing the local form of IGF-1 (mIGF-1) [43, 176]. Moreover, we demonstrated that the local expression of mIGF-1 transgene accelerates the regenerative process of injured skeletal muscle, modulating the inflammatory response and limiting fibrosis [44]. At the molecular level, mIGF-1 expression significantly downregulated proinflammatory cytokines, such as TNF- α and IL-1 β , and modulated key players of the inflammatory response, such as macrophage migration inhibitory factor (MIF), high mobility group protein-1 (HMGB1), and transcription NF- κ B [44]. The rapid restoration of injured mIGF-1 transgenic muscle was also associated with connective tissue remodeling and a rapid recovery of functional properties.

Wehling et al. [177] reported that the depletion of macrophages in the mdx mouse model at the early, acute peak of muscle pathology produced large reductions in lesions in the plasmalemma of muscle fibers, showing that muscle macrophages that are present during the acute, degenerative stage of mdx dystrophy are highly cytolytic and that they play a central role in the pathogenesis of muscular dystrophy [178]. Additionally, Villalta and coworkers [83] reported that arginase-expressing M2a macrophages can reduce the muscle cell damage caused by M1 macrophages in mdx dystrophy, improving satellite cell proliferation.

These data suggest that, by modulating the inflammatory response and reducing fibrosis, it is possible to create a qualitatively different environment for sustaining more efficient muscle regeneration and repair.

However, an important issue is whether aged muscle stem cells are in some way intrinsically defective in responding to regenerative stimuli. This question has been addressed by two recent studies [179, 180]. It has been demonstrated that geriatric age induces intrinsic alterations in the functions of muscle stem cells, which cannot be rejuvenated by a young

host environment [179]. The authors found that the dominant factor that induces geriatric processes in satellite cells is the master regulator of senescence p16INK4a (Cdkn2a). Thus, p16INK4a silencing restored satellite cell quiescence, whereas ectopic p16INK4a expression in quiescent young satellite cells prevented their activation [179].

In another study, Cosgrove and collaborators [180] demonstrated that the intrinsically defective capacity of geriatric muscle stem cells to efficiently respond to a young recipient muscle microenvironment depends on the elevated activity of the p38 α and p38 β mitogen-activated kinase pathway. The transient inhibition of p38 α and p38 β in geriatric muscle stem cells promoted their rapid expansion and rejuvenated their potential for regeneration [180].

In summary, the alteration in muscle regeneration, observed in different pathologic conditions, can be due to intrinsic alterations that render muscle stem cells defective in responding to regenerative stimuli and to a hostile microenvironment that inhibits stem cell activity [181].

Conflict of Interests

The author declares that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

Work in the author's laboratory has been supported by Tel-ethon, AFM, PRIN, and ASI.

References

- [1] J. P. Brocques, "Amphibian limb regeneration: rebuilding a complex structure," *Science*, vol. 276, no. 5309, pp. 81–87, 1997.
- [2] E. M. Tanaka, "Regeneration: if they can do it, why can't we?" *Cell*, vol. 113, no. 5, pp. 559–562, 2003.
- [3] L. E. Iten and S. V. Bryant, "Forelimb regeneration from different levels of amputation in the newt, *Notophthalmus viridescens*: length, rate, and stages," *Wilhelm Roux's Archives of Developmental Biology*, vol. 173, no. 4, pp. 263–282, 1973.
- [4] E. M. Tanaka, A. A. F. Gann, P. B. Gates, and J. P. Brocques, "Newt myotubes reenter the cell cycle by phosphorylation of the retinoblastoma protein," *Journal of Cell Biology*, vol. 136, no. 1, pp. 155–165, 1997.
- [5] M. Kragl, D. Knapp, E. Nacu et al., "Cells keep a memory of their tissue origin during axolotl limb regeneration," *Nature*, vol. 460, no. 7251, pp. 60–65, 2009.
- [6] S. Tajbakhsh and G. Cossu, "Establishing myogenic identity during somitogenesis," *Current Opinion in Genetics and Development*, vol. 7, no. 5, pp. 634–641, 1997.
- [7] T. J. Hawke and D. J. Garry, "Myogenic satellite cells: physiology to molecular biology," *Journal of Applied Physiology*, vol. 91, no. 2, pp. 534–551, 2001.
- [8] S. B. P. Chargé and M. A. Rudnicki, "Cellular and molecular regulation of muscle regeneration," *Physiological Reviews*, vol. 84, no. 1, pp. 209–238, 2004.
- [9] M. Goulding, A. Lumsden, and A. J. Paquette, "Regulation of Pax-3 expression in the dermomyotome and its role in muscle development," *Development*, vol. 120, no. 4, pp. 957–971, 1994.

- [10] B. A. Williams and C. P. Ordahl, "Pax-3 expression in segmental mesoderm marks early stages in myogenic cell specification," *Development*, vol. 120, no. 4, pp. 785–796, 1994.
- [11] E. Bober, T. Franz, H. Arnold, P. Gruss, and P. Tremblay, "Pax-3 is required for the development of limb muscles: a possible role for the migration of dermomyotomal muscle progenitor cells," *Development*, vol. 120, no. 3, pp. 603–612, 1994.
- [12] G. Daston, E. Lamar, M. Olivier, and M. Goulding, "Pax-3 is necessary for migration but not differentiation of limb muscle precursors in the mouse," *Development*, vol. 122, no. 3, pp. 1017–1027, 1996.
- [13] P. Tremblay, S. Dietrich, M. Mericskay, F. R. Schubert, Z. Li, and D. Paulin, "A crucial role for Pax3 in the development of the hypaxial musculature and the long-range migration of muscle precursors," *Developmental Biology*, vol. 203, no. 1, pp. 49–61, 1998.
- [14] B. Jostes, C. Walther, and P. Gruss, "The murine paired box gene, Pax7, is expressed specifically during the development of the nervous and muscular system," *Mechanisms of Development*, vol. 33, no. 1, pp. 27–37, 1990.
- [15] P. Seale, L. A. Sabourin, A. Girgis-Gabardo, A. Mansouri, P. Gruss, and M. A. Rudnicki, "Pax7 is required for the specification of myogenic satellite cells," *Cell*, vol. 102, no. 6, pp. 777–786, 2000.
- [16] A. Mansouri, A. Stoykova, M. Torres, and P. Gruss, "Dysgenesis of cephalic neural crest derivatives in Pax7^{-/-} mutant mice," *Development*, vol. 122, no. 3, pp. 831–838, 1996.
- [17] J. A. Epstein, D. N. Shapiro, J. Cheng, P. Y. P. Lam, and R. L. Maas, "Pax3 modulates expression of the c-met receptor during limb muscle development," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 93, no. 9, pp. 4213–4218, 1996.
- [18] F. Bladt, D. Riethmacher, S. Isenmann, A. Aguzzi, and C. Birchmeier, "Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud," *Nature*, vol. 376, no. 6543, pp. 768–771, 1995.
- [19] S. J. Tapscott, "The circuitry of a master switch: myoD and the regulation of skeletal muscle gene transcription," *Development*, vol. 132, no. 12, pp. 2685–2695, 2005.
- [20] C. A. Berkes and S. J. Tapscott, "MyoD and the transcriptional control of myogenesis," *Seminars in Cell and Developmental Biology*, vol. 16, no. 4–5, pp. 585–595, 2005.
- [21] S. Tajbakhsh, E. Bober, C. Babinet, S. Pournin, H. Arnold, and M. Buckingham, "Gene targeting the myf-5 locus with nlacZ reveals expression of this myogenic factor in mature skeletal muscle fibres as well as early embryonic muscle," *Developmental Dynamics*, vol. 206, pp. 291–300, 1996.
- [22] M.-O. Ott, E. Bober, G. Lyons, H. Arnold, and M. Buckingham, "Early expression of the myogenic regulatory gene, myf-5, in precursor cells of skeletal muscle in the mouse embryo," *Development*, vol. 111, no. 4, pp. 1097–1107, 1991.
- [23] R. Spörle, T. Günther, M. Struwe, and K. Schughart, "Severe defects in the formation of epaxial musculature in open brain (opb) mutant mouse embryos," *Development*, vol. 122, no. 1, pp. 79–86, 1996.
- [24] M. Buckingham, "Making muscle in mammals," *Trends in Genetics*, vol. 8, no. 4, pp. 144–149, 1992.
- [25] D. Sassoon, G. Lyons, W. E. Wright et al., "Expression of two myogenic regulatory factors myogenin and MyoD1 during mouse embryogenesis," *Nature*, vol. 341, no. 6240, pp. 303–307, 1989.
- [26] M. A. Rudnicki, P. N. J. Schnegelsberg, R. H. Stead, T. Braun, H. H. Arnold, and R. Jaenisch, "MyoD or Myf-5 is required for the formation of skeletal muscle," *Cell*, vol. 75, no. 7, pp. 1351–1359, 1993.
- [27] P. Hasty, A. Bradley, J. H. Morris et al., "Muscle deficiency and neonatal death in mice with a targeted mutation in the myogenin gene," *Nature*, vol. 364, no. 6437, pp. 501–506, 1993.
- [28] Y. Nabeshima, K. Hanaoka, M. Hayasaka et al., "Myogenin gene disruption results in perinatal lethality because of severe muscle defect," *Nature*, vol. 364, no. 6437, pp. 532–535, 1993.
- [29] L. Kassar-Duchossoy, B. Gayraud-Morel, D. Gomès et al., "Mrf4 determines skeletal muscle identity in Myf5: MyoD double-mutant mice," *Nature*, vol. 431, pp. 466–471, 2004.
- [30] A. Musaro, M. G. C. de Angelis, A. Germani, C. Ciccarelli, M. Molinaro, and B. M. Zani, "Enhanced expression of myogenic regulatory genes in aging skeletal muscle," *Experimental Cell Research*, vol. 221, no. 1, pp. 241–248, 1995.
- [31] E. I. Dedkov, T. Y. Kostrominova, A. B. Borisov, and B. M. Carlson, "MyoD and myogenin protein expression in skeletal muscles of senile rats," *Cell and Tissue Research*, vol. 311, no. 3, pp. 401–416, 2003.
- [32] D. Palacios and P. L. Puri, "The epigenetic network regulating muscle development and regeneration," *Journal of Cellular Physiology*, vol. 207, no. 1, pp. 1–11, 2006.
- [33] E. A. Miska, E. Langley, D. Wolf, C. Karlsson, J. Pines, and T. Kouzarides, "Differential localization of HDAC4 orchestrates muscle differentiation," *Nucleic Acids Research*, vol. 29, no. 16, pp. 3439–3447, 2001.
- [34] M. Haberland, R. L. Montgomery, and E. N. Olson, "The many roles of histone deacetylases in development and physiology: implications for disease and therapy," *Nature Reviews Genetics*, vol. 10, no. 1, pp. 32–42, 2009.
- [35] T. E. Callis, Z. Deng, J.-F. Chen, and D.-Z. Wang, "Muscling through the microRNA world," *Experimental Biology and Medicine*, vol. 233, no. 2, pp. 131–138, 2008.
- [36] E. van Rooij, N. Liu, and E. N. Olson, "MicroRNAs flex their muscles," *Trends in Genetics*, vol. 24, no. 4, pp. 159–166, 2008.
- [37] A. H. Williams, N. Liu, E. van Rooij, and E. N. Olson, "MicroRNA control of muscle development and disease," *Current Opinion in Cell Biology*, vol. 21, no. 3, pp. 461–469, 2009.
- [38] D. P. Bartel, "MicroRNAs: genomics, biogenesis, mechanism, and function," *Cell*, vol. 116, no. 2, pp. 281–297, 2004.
- [39] N. S. Asli, M. E. Pitulescu, and M. Kessel, "MicroRNAs in organogenesis and disease," *Current Molecular Medicine*, vol. 8, no. 8, pp. 698–710, 2008.
- [40] J. F. Chen, E. M. Mandel, J. M. Thomson et al., "The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation," *Nature Genetics*, vol. 38, no. 2, pp. 228–233, 2006.
- [41] R. Couteaux, J. Mira, and A. d'Albis, "Regeneration of muscles after cardiotoxin injury. I. Cytological aspects," *Biology of the Cell*, vol. 62, no. 2, pp. 171–182, 1988.
- [42] A. d'Albis, R. Couteaux, C. Janmot, A. Roulet, and J. C. Mira, "Regeneration after cardiotoxin injury of innervated and denervated slow and fast muscles of mammals. Myosin isoform analysis," *European Journal of Biochemistry*, vol. 174, no. 1, pp. 103–110, 1988.
- [43] A. Musarò, K. McCullagh, A. Paul et al., "Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle," *Nature Genetics*, vol. 27, no. 2, pp. 195–200, 2001.

- [44] L. Pelosi, C. Giacinti, C. Nardis et al., "Local expression of IGF-1 accelerates muscle regeneration by rapidly modulating inflammatory cytokines and chemokines," *The FASEB Journal*, vol. 21, no. 7, pp. 1393–1402, 2007.
- [45] R. Matsuda, A. Nishikawa, and H. Tanaka, "Visualization of dystrophic muscle fibers in Mdx mouse by vital staining with Evans blue: evidence of apoptosis in dystrophin-deficient muscle," *The Journal of Biochemistry*, vol. 118, no. 5, pp. 959–964, 1995.
- [46] M. D. Grounds, "Phagocytosis of necrotic muscle in muscle isografts is influenced by the strain, age, and sex of host mice," *Journal of Pathology*, vol. 153, no. 1, pp. 71–82, 1987.
- [47] J. G. Tidball and M. Wehling-Henricks, "Macrophages promote muscle membrane repair and muscle fibre growth and regeneration during modified muscle loading in mice in vivo," *Journal of Physiology*, vol. 578, no. 1, pp. 327–336, 2007.
- [48] M. Summan, G. L. Warren, R. R. Mercer et al., "Macrophages and skeletal muscle regeneration: a clodronate-containing liposome depletion study," *The American Journal of Physiology: Regulatory Integrative and Comparative Physiology*, vol. 290, no. 6, pp. R1488–R1495, 2006.
- [49] J. G. Tidball, "Inflammatory processes in muscle injury and repair," *The American Journal of Physiology: Regulatory Integrative and Comparative Physiology*, vol. 288, no. 2, pp. R345–R353, 2005.
- [50] C. F. P. Teixeira, S. R. Zamuner, J. P. Zuliani et al., "Neutrophils do not contribute to local tissue damage, but play a key role in skeletal muscle regeneration, in mice injected with Bothrops asper snake venom," *Muscle and Nerve*, vol. 28, no. 4, pp. 449–459, 2003.
- [51] R. A. Fielding, T. J. Manfredi, W. Ding, M. A. Fiatarone, W. J. Evans, and J. G. Cannon, "Acute phase response in exercise III. Neutrophil and IL-1 β accumulation in skeletal muscle," *American Journal of Physiology—Regulatory Integrative and Comparative Physiology*, vol. 265, no. 1, part 2, pp. R166–R172, 1993.
- [52] A. N. Belcastro, G. D. Arthur, T. A. Albisser, and D. A. Raj, "Heart, liver, and skeletal muscle myeloperoxidase activity during exercise," *Journal of Applied Physiology*, vol. 80, no. 4, pp. 1331–1335, 1996.
- [53] T. K. Kishimoto and R. Rothlein, "Integrins, ICAMs, and selectins: role and regulation of adhesion molecules in neutrophil recruitment to inflammatory sites," *Advances in Pharmacology*, vol. 25, pp. 117–169, 1994.
- [54] W. A. Muller, "Leukocyte-endothelial-cell interactions in leukocyte transmigration and the inflammatory response," *Trends in Immunology*, vol. 24, no. 6, pp. 327–334, 2003.
- [55] B. Walzog and P. Gaehtgens, "Adhesion molecules: the path to a new understanding of acute inflammation," *News in Physiological Sciences*, vol. 15, no. 3, pp. 107–113, 2000.
- [56] M. Sixt, R. Hallmann, O. Wendler, K. Scharffetter-Kochanek, and L. M. Sorokin, "Cell adhesion and migration properties of β 2-integrin negative polymorphonuclear granulocytes on defined extracellular matrix molecules: relevance for leukocyte extravasation," *The Journal of Biological Chemistry*, vol. 276, no. 22, pp. 18878–18887, 2001.
- [57] F. X. Pizza, J. M. Peterson, J. H. Baas, and T. J. Koh, "Neutrophils contribute to muscle injury and impair its resolution after lengthening contractions in mice," *Journal of Physiology*, vol. 562, no. 3, pp. 899–913, 2005.
- [58] B. A. St. Pierre and J. G. Tidball, "Differential response of macrophage subpopulations to soleus muscle reloading after rat hindlimb suspension," *Journal of Applied Physiology*, vol. 77, no. 1, pp. 290–297, 1994.
- [59] L. Arnold, A. Henry, F. Poron et al., "Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis," *Journal of Experimental Medicine*, vol. 204, no. 5, pp. 1057–1069, 2007.
- [60] M. Saclier, S. Cuvellier, M. Magnan, R. Mounier, and B. Chazaud, "Monocyte/macrophage interactions with myogenic precursor cells during skeletal muscle regeneration," *The FEBS Journal*, vol. 280, no. 17, pp. 4118–4130, 2013.
- [61] I. S. McLennan, "Resident macrophages (ED2- and ED3-positive) do not phagocytose degenerating rat skeletal muscle fibres," *Cell and Tissue Research*, vol. 272, no. 1, pp. 193–196, 1993.
- [62] H. Honda, H. Kimura, and A. Rostami, "Demonstration and phenotypic characterization of resident macrophages in rat skeletal muscle," *Immunology*, vol. 70, no. 2, pp. 272–277, 1990.
- [63] A. Pimorady-Esfahani, M. D. Grounds, and P. G. McMenamin, "Macrophages and dendritic cells in normal and regenerating murine skeletal muscle," *Muscle Nerve*, vol. 20, pp. 158–166, 1997.
- [64] T. Varga, R. Mounier, P. Gogolak, S. Poliska, B. Chazaud, and L. Nagy, "Tissue LyC6- macrophages are generated in the absence of circulating LyC6- monocytes and Nur77 in a model of muscle regeneration," *Journal of Immunology*, vol. 191, no. 11, pp. 5695–5701, 2013.
- [65] F. Geissmann, S. Jung, and D. R. Littman, "Blood monocytes consist of two principal subsets with distinct migratory properties," *Immunity*, vol. 19, no. 1, pp. 71–82, 2003.
- [66] F. Geissmann, C. Auffray, R. Palframan et al., "Blood monocytes: distinct subsets, how they relate to dendritic cells, and their possible roles in the regulation of T-cell responses," *Immunology and Cell Biology*, vol. 86, no. 5, pp. 398–408, 2008.
- [67] B. Chazaud, M. Brigitte, H. Yacoub-Youssef et al., "Dual and beneficial roles of macrophages during skeletal muscle regeneration," *Exercise and Sport Sciences Reviews*, vol. 37, no. 1, pp. 18–22, 2009.
- [68] R. D. Stout, C. Jiang, B. Matta, I. Tietzel, S. K. Watkins, and J. Suttles, "Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences," *The Journal of Immunology*, vol. 175, no. 1, pp. 342–349, 2005.
- [69] A. Mantovani, A. Sica, S. Sozzani, P. Allavena, A. Vecchi, and M. Locati, "The chemokine system in diverse forms of macrophage activation and polarization," *Trends in Immunology*, vol. 25, no. 12, pp. 677–686, 2004.
- [70] S. S. Rabinowitz and S. Gordon, "Macrosialin, a macrophage-restricted membrane sialoprotein differentially glycosylated in response to inflammatory stimuli," *Journal of Experimental Medicine*, vol. 174, no. 4, pp. 827–836, 1991.
- [71] M. P. Ramprasad, W. Fischer, J. L. Witztum, G. R. Sambrano, O. Quehenberger, and D. Steinberg, "The 94- to 97-kDa mouse macrophage membrane protein that recognizes oxidized low density lipoprotein and phosphatidylserine-rich liposomes is identical to macrosialin, the mouse homologue of human CD68," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 92, no. 21, pp. 9580–9584, 1995.
- [72] B. B. Krippendorf and D. A. Riley, "Distinguishing unloading-versus reloading-induced changes in rat soleus muscle," *Muscle & Nerve*, vol. 16, no. 1, pp. 99–108, 1993.
- [73] B. Deng, M. Wehling-Henricks, S. A. Villalta, Y. Wang, and J. G. Tidball, "IL-10 triggers changes in macrophage phenotype that promote muscle growth and regeneration," *Journal of Immunology*, vol. 189, no. 7, pp. 3669–3680, 2012.

- [74] T. Lawrence and G. Natoli, "Transcriptional regulation of macrophage polarization: enabling diversity with identity," *Nature Reviews Immunology*, vol. 11, no. 11, pp. 750–761, 2011.
- [75] R. Mounier, M. Th  ret, L. Arnold et al., "AMPK α 1 regulates macrophage skewing at the time of resolution of inflammation during skeletal muscle regeneration," *Cell Metabolism*, vol. 18, no. 2, pp. 251–264, 2013.
- [76] D. Sag, D. Carling, R. D. Stout, and J. Suttles, "Adenosine 5'-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype," *Journal of Immunology*, vol. 181, no. 12, pp. 8633–8641, 2008.
- [77] V. Krishnan and B. C. Yaden, "Macrofinancing efficient remodeling of damaged muscle tissue," *Cell Metabolism*, vol. 18, no. 2, pp. 149–151, 2013.
- [78] Y. Bordon, "Macrophages: metabolic master prompts a change of tack," *Nature Reviews Immunology*, vol. 13, p. 706, 2013.
- [79] O. Takeuchi and S. Akira, "Epigenetic control of macrophage polarization," *European Journal of Immunology*, vol. 41, no. 9, pp. 2490–2493, 2011.
- [80] S. Banerjee, H. Cui, N. Xie et al., "miR-125a-5p regulates differential activation of macrophages and inflammation," *The Journal of Biological Chemistry*, vol. 288, no. 49, pp. 35428–35436, 2013.
- [81] S. Banerjee, N. Xie, H. Cui et al., "MicroRNA let-7c regulates macrophage polarization," *Journal of Immunology*, vol. 190, no. 12, pp. 6542–6549, 2013.
- [82] J. G. Tidball and S. A. Villalta, "Regulatory interactions between muscle and the immune system during muscle regeneration," *The American Journal of Physiology—Regulatory Integrative and Comparative Physiology*, vol. 298, no. 5, pp. R1173–R1187, 2010.
- [83] S. A. Villalta, H. X. Nguyen, B. Deng, T. Gotoh, and J. G. Tidball, "Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy," *Human Molecular Genetics*, vol. 18, no. 3, pp. 482–496, 2009.
- [84] M. R. Douglas, K. E. Morrison, M. Salmon, and C. D. Buckley, "Why does inflammation persist: a dominant role for the stromal microenvironment?" *Expert Reviews in Molecular Medicine*, vol. 4, no. 25, pp. 1–18, 2002.
- [85] A. Mauro, "Satellite cell of skeletal muscle fibers," *The Journal of Biophysical and Biochemical Cytology*, vol. 9, pp. 493–495, 1961.
- [86] J. Scharner and P. S. Zammit, "The muscle satellite cell at 50: the formative years," *Skeletal Muscle*, vol. 1, no. 1, article 28, 2011.
- [87] B. Gayraud-Morel, F. Chr  tien, and S. Tajbakhsh, "Skeletal muscle as a paradigm for regenerative biology and medicine," *Regenerative Medicine*, vol. 4, no. 2, pp. 293–319, 2009.
- [88] P. S. Zammit, J. P. Golding, Y. Nagata, V. Hudon, T. A. Partridge, and J. R. Beauchamp, "Muscle satellite cells adopt divergent fates: a mechanism for self-renewal?" *The Journal of Cell Biology*, vol. 166, no. 3, pp. 347–357, 2004.
- [89] R. Tatsumi, J. E. Anderson, C. J. Nevoret, O. Halevy, and R. E. Allen, "HGF/SF is present in normal adult skeletal muscle and is capable of activating satellite cells," *Developmental Biology*, vol. 194, no. 1, pp. 114–128, 1998.
- [90] A. Irintchev, M. Zeschnigk, A. Starzinski-Powitz, and A. Wernig, "Expression pattern of M-cadherin in normal, denervated, and regenerating mouse muscles," *Developmental Dynamics*, vol. 199, no. 4, pp. 326–337, 1994.
- [91] D. J. Garry, Q. Yang, R. Bassel-Duby, and R. S. Williams, "Persistent expression of MNF identifies myogenic stem cells in postnatal muscles," *Developmental Biology*, vol. 188, no. 2, pp. 280–294, 1997.
- [92] G. Mechtersheimer, M. Staudter, and P. Moller, "Expression of the natural killer (NK) cell-associated antigen CD56(Leu-19), which is identical to the 140-kDa isoform of N-CAM, in neural and skeletal muscle cells and tumors derived therefrom," *Annals of the New York Academy of Sciences*, vol. 650, pp. 311–316, 1992.
- [93] D. D. Cornelison, M. S. Filla, H. M. Stanley, A. C. Rapraeger, and B. B. Olwin, "Syndecan-3 and syndecan-4 specifically mark skeletal muscle satellite cells and are implicated in satellite cell maintenance and muscle regeneration," *Developmental Biology*, vol. 239, no. 1, pp. 79–94, 2001.
- [94] J. R. Beauchamp, L. Heslop, D. S. W. Yu et al., "Expression of CD34 and Myf5 defines the majority of quiescent adult skeletal muscle satellite cells," *Journal of Cell Biology*, vol. 151, no. 6, pp. 1221–1234, 2000.
- [95] D. Volonte, Y. Liu, and F. Galbiati, "The modulation of caveolin-1 expression controls satellite cell activation during muscle repair," *FASEB Journal*, vol. 19, no. 2, pp. 237–239, 2005.
- [96] K. Schmidt, G. Glaser, A. Wernig, M. Wegner, and O. Rosorius, "Sox8 is a specific marker for muscle satellite cells and inhibits myogenesis," *The Journal of Biological Chemistry*, vol. 278, no. 32, pp. 29769–29775, 2003.
- [97] H. J. Lee, W. G  ring, M. Ochs et al., "Sox15 is required for skeletal muscle regeneration," *Molecular and Cellular Biology*, vol. 24, no. 19, pp. 8428–8436, 2004.
- [98] T. L. Jesse, R. LaChance, M. F. Iademarco, and D. C. Dean, "Interferon regulatory factor-2 is a transcriptional activator in muscle where it regulates expression of vascular cell adhesion molecule-1," *Journal of Cell Biology*, vol. 140, no. 5, pp. 1265–1276, 1998.
- [99] V. F. Gnocchi, R. B. White, Y. Ono, J. A. Ellis, and P. S. Zammit, "Further characterisation of the molecular signature of quiescent and activated mouse muscle satellite cells," *PLoS ONE*, vol. 4, no. 4, Article ID e5205, 2009.
- [100] R. I. Sherwood, J. L. Christensen, I. M. Conboy et al., "Isolation of adult mouse myogenic progenitors: functional heterogeneity of cells within and engrafting skeletal muscle," *Cell*, vol. 119, no. 4, pp. 543–554, 2004.
- [101] S. Fukada, A. Uezumi, M. Ikemoto et al., "Molecular signature of quiescent satellite cells in adult skeletal muscle," *Stem Cells*, vol. 25, no. 10, pp. 2448–2459, 2007.
- [102] S. Fukada, M. Yamaguchi, H. Kokubo et al., "Hes1 and Hes3 are essential to generate undifferentiated quiescent satellite cells and to maintain satellite cell numbers," *Development*, vol. 138, no. 21, pp. 4609–4619, 2011.
- [103] F. Relaix, D. Montarras, S. Zaffran et al., "Pax3 and Pax7 have distinct and overlapping functions in adult muscle progenitor cells," *Journal of Cell Biology*, vol. 172, no. 1, pp. 91–102, 2006.
- [104] M. Buckingham, "Skeletal muscle progenitor cells and the role of Pax genes," *Comptes Rendus—Biologies*, vol. 330, no. 6–7, pp. 530–533, 2007.
- [105] S. Creuzet, L. Lescaudron, Z. Li, and J. Fontaine-P  rus, "MyoD, myogenin, and desmin-nls-lacZ transgene emphasize the distinct patterns of satellite cell activation in growth and regeneration," *Experimental Cell Research*, vol. 243, no. 2, pp. 241–253, 1998.
- [106] Z. Yablonka-Reuveni and A. J. Rivera, "Temporal expression of regulatory and structural muscle proteins during myogenesis of satellite cells on isolated adult rat fibers," *Developmental Biology*, vol. 164, no. 2, pp. 588–603, 1994.

- [107] P. S. Zammit, T. A. Partridge, and Z. Yablonka-Reuveni, "The skeletal muscle satellite cell: the stem cell that came in from the cold," *Journal of Histochemistry & Cytochemistry*, vol. 54, no. 11, pp. 1177–1191, 2006.
- [108] K. Day, G. Shefer, A. Shearer, and Z. Yablonka-Reuveni, "The depletion of skeletal muscle satellite cells with age is concomitant with reduced capacity of single progenitors to produce reserve progeny," *Developmental Biology*, vol. 340, no. 2, pp. 330–343, 2010.
- [109] Z. Yablonka-Reuveni, M. A. Rudnicki, A. J. Rivera, M. Primig, J. E. Anderson, and P. Natanson, "The transition from proliferation to differentiation is delayed in satellite cells from mice lacking MyoD," *Developmental Biology*, vol. 210, no. 2, pp. 440–455, 1999.
- [110] L. Boldrin, F. Muntoni, and J. E. Morgan, "Are human and mouse satellite cells really the same?" *Journal of Histochemistry and Cytochemistry*, vol. 58, no. 11, pp. 941–955, 2010.
- [111] K. Day, G. Shefer, J. B. Richardson, G. Enikolopov, and Z. Yablonka-Reuveni, "Nestin-GFP reporter expression defines the quiescent state of skeletal muscle satellite cells," *Developmental Biology*, vol. 304, no. 1, pp. 246–259, 2007.
- [112] Y. Nagata, H. Kobayashi, M. Umeda et al., "Sphingomyelin levels in the plasma membrane correlate with the activation state of muscle satellite cells," *Journal of Histochemistry and Cytochemistry*, vol. 54, no. 4, pp. 375–384, 2006.
- [113] F. Relaix and P. S. Zammit, "Satellite cells are essential for skeletal muscle regeneration: the cell on the edge returns centre stage," *Development*, vol. 139, no. 16, pp. 2845–2856, 2012.
- [114] Z. Yablonka-Reuveni, K. Day, A. Vine, and G. Shefer, "Defining the transcriptional signature of skeletal muscle stem cells," *Journal of Animal Science*, vol. 86, supplement 14, pp. E207–E216, 2008.
- [115] I. M. Conboy and T. A. Rando, "The regulation of Notch signaling controls satellite cell activation and cell fate determination in postnatal myogenesis," *Developmental Cell*, vol. 3, no. 3, pp. 397–409, 2002.
- [116] S. Kuang, K. Kuroda, F. Le Grand, and M. A. Rudnicki, "Asymmetric self-renewal and commitment of satellite stem cells in muscle," *Cell*, vol. 129, no. 5, pp. 999–1010, 2007.
- [117] K. Schuster-Gossler, R. Cordes, and A. Gossler, "Premature myogenic differentiation and depletion of progenitor cells cause severe muscle hypotrophy in Delta1 mutants," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 2, pp. 537–542, 2007.
- [118] C. R. R. Bjornson, T. H. Cheung, L. Liu, P. V. Tripathi, K. M. Steeper, and T. A. Rando, "Notch signaling is necessary to maintain quiescence in adult muscle stem cells," *Stem Cells*, vol. 30, no. 2, pp. 232–242, 2012.
- [119] P. Mourikis, R. Sambasivan, D. Castel, P. Rocheteau, V. Bizzarro, and S. Tajbakhsh, "A critical requirement for notch signaling in maintenance of the quiescent skeletal muscle stem cell state," *Stem Cells*, vol. 30, no. 2, pp. 243–252, 2012.
- [120] Y. Wen, P. Bi, W. Liu, A. Asakura, C. Keller, and S. Kuang, "Constitutive Notch Activation Upregulates Pax7 and promotes the self-renewal of skeletal muscle satellite cells," *Molecular and Cellular Biology*, vol. 32, no. 12, pp. 2300–2311, 2012.
- [121] R. M. George, S. Biressi, B. J. Beres et al., "Numb-deficient satellite cells have regeneration and proliferation defects," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 110, pp. 18549–18554, 2013.
- [122] A. S. Brack, I. M. Conboy, M. J. Conboy, J. Shen, and T. A. Rando, "A temporal switch from notch to Wnt signaling in muscle stem cells is necessary for normal adult myogenesis," *Cell Stem Cell*, vol. 2, no. 1, pp. 50–59, 2008.
- [123] A. J. Wagers, "Wnt not, waste not," *Cell Stem Cell*, vol. 2, no. 1, pp. 6–7, 2008.
- [124] Z. Yan, S. Choi, X. Liu et al., "Highly coordinated gene regulation in mouse skeletal muscle regeneration," *The Journal of Biological Chemistry*, vol. 278, no. 10, pp. 8826–8836, 2003.
- [125] L. Giordani and P. L. Puri, "Epigenetic control of skeletal muscle regeneration: integrating genetic determinants and environmental changes," *FEBS Journal*, vol. 280, no. 17, pp. 4014–4025, 2013.
- [126] D. Cacchiarelli, J. Martone, E. Girardi et al., "MicroRNAs involved in molecular circuitries relevant for the duchenne muscular dystrophy pathogenesis are controlled by the dystrophin/nNOS pathway," *Cell Metabolism*, vol. 12, no. 4, pp. 341–351, 2010.
- [127] T. H. Cheung, N. L. Quach, G. W. Charville et al., "Maintenance of muscle stem-cell quiescence by microRNA-489," *Nature*, vol. 482, no. 7386, pp. 524–528, 2012.
- [128] R. Bischoff, "The satellite cell and muscle regeneration," in *Myology*, A. G. Engel and C. Franzini-Armstrong, Eds., pp. 97–118, McGraw-Hill, New York, NY, USA, 1994.
- [129] E. Schultz and B. H. Lipton, "Skeletal muscle satellite cells: changes in proliferation potential as a function of age," *Mechanisms of Ageing and Development*, vol. 20, no. 4, pp. 377–383, 1982.
- [130] M. D. Grounds and J. K. McGeachie, "A model of myogenesis in vivo, derived from detailed autoradiographic studies of regenerating skeletal muscle, challenges the concept of quantal mitosis," *Cell and Tissue Research*, vol. 250, no. 3, pp. 563–569, 1987.
- [131] F. P. Moss and C. P. Leblond, "Satellite cells as the source of nuclei in muscles of growing rats," *Anatomical Record*, vol. 170, no. 4, pp. 421–435, 1971.
- [132] E. Schultz, "Satellite cell proliferative compartments in growing skeletal muscles," *Developmental Biology*, vol. 175, no. 1, pp. 84–94, 1996.
- [133] P. Rocheteau, B. Gayraud-Morel, I. Siegl-Cachedenier, M. A. Blasco, and S. Tajbakhsh, "A subpopulation of adult skeletal muscle stem cells retains all template DNA strands after cell division," *Cell*, vol. 148, no. 1–2, pp. 112–125, 2012.
- [134] S. Günther, J. Kim, S. Kostin, C. Lepper, C. Fan, and T. Braun, "Myf5-positive satellite cells contribute to Pax7-dependent long-term maintenance of adult muscle stem cells," *Cell Stem Cell*, vol. 13, pp. 590–601, 2013.
- [135] S. Oustanina, G. Hause, and T. Braun, "Pax7 directs postnatal renewal and propagation of myogenic satellite cells but not their specification," *EMBO Journal*, vol. 23, no. 16, pp. 3430–3439, 2004.
- [136] C. Lepper, S. J. Conway, and C. M. Fan, "Adult satellite cells and embryonic muscle progenitors have distinct genetic requirements," *Nature*, vol. 460, no. 7255, pp. 627–631, 2009.
- [137] J. von Maltzahn, A. E. Jones, R. J. Parks, and M. A. Rudnicki, "Pax7 is critical for the normal function of satellite cells in adult skeletal muscle," *Proceedings of the National Academy of Sciences of the USA*, vol. 110, no. 41, pp. 16474–16479, 2013.
- [138] G. Messina, S. Biressi, and G. Cossu, "Non muscle stem cells and muscle regeneration," in *Skeletal Muscle Repair and Regeneration*, S. Schiaffino and T. Partridge, Eds., Advances in Muscle Research, pp. 65–84, Springer, Dordrecht, The Netherlands, 2008.

- [139] L. de Angelis, L. Berghella, M. Coletta et al., “Skeletal myogenic progenitors originating from embryonic dorsal aorta coexpress endothelial and myogenic markers and contribute to postnatal muscle growth and regeneration,” *Journal of Cell Biology*, vol. 147, no. 4, pp. 869–877, 1999.
- [140] S. Kuang, S. B. Chargé, P. Seale, M. Huh, and M. A. Rudnicki, “Distinct roles for Pax7 and Pax3 in adult regenerative myogenesis,” *Journal of Cell Biology*, vol. 172, no. 1, pp. 103–113, 2006.
- [141] A. Poleskaya, P. Seale, and M. A. Rudnicki, “Wnt signaling induces the myogenic specification of resident CD45⁺ adult stem cells during muscle regeneration,” *Cell*, vol. 113, no. 7, pp. 841–852, 2003.
- [142] T. Tamaki, A. Akatsuka, K. Ando et al., “Identification of myogenic-endothelial progenitor cells in the interstitial spaces of skeletal muscle,” *The Journal of Cell Biology*, vol. 157, no. 4, pp. 571–577, 2002.
- [143] K. J. Mitchell, A. Pannérec, B. Cadot et al., “Identification and characterization of a non-satellite cell muscle resident progenitor during postnatal development,” *Nature Cell Biology*, vol. 12, no. 3, pp. 257–266, 2010.
- [144] M. C. Valero, H. D. Huntsman, J. Liu, K. Zou, and M. D. Boppart, “Eccentric exercise facilitates mesenchymal stem cell appearance in skeletal muscle,” *PLoS ONE*, vol. 7, no. 1, Article ID e29760, 2012.
- [145] M. N. Wosczyzna, A. A. Biswas, C. A. Cogswell, and D. J. Goldhamer, “Multipotent progenitors resident in the skeletal muscle interstitium exhibit robust BMP-dependent osteogenic activity and mediate heterotopic ossification,” *Journal of Bone and Mineral Research*, vol. 27, no. 5, pp. 1004–1017, 2012.
- [146] A. Asakura, P. Seale, A. Girgis-Gabardo, and M. A. Rudnicki, “Myogenic specification of side population cells in skeletal muscle,” *Journal of Cell Biology*, vol. 159, no. 1, pp. 123–134, 2002.
- [147] E. Gussoni, Y. Soneoka, C. D. Strickland et al., “Dystrophin expression in the mdx mouse restored by stem cell transplantation,” *Nature*, vol. 401, no. 6751, pp. 390–394, 1999.
- [148] A. Uezumi, T. Ito, D. Morikawa et al., “Fibrosis and adipogenesis originate from a common mesenchymal progenitor in skeletal muscle,” *Journal of Cell Science*, vol. 124, no. 21, pp. 3654–3664, 2011.
- [149] A. Uezumi, S. Fukada, N. Yamamoto, S. Takeda, and K. Tsuchida, “Mesenchymal progenitors distinct from satellite cells contribute to ectopic fat cell formation in skeletal muscle,” *Nature Cell Biology*, vol. 12, no. 2, pp. 143–152, 2010.
- [150] S. E. Mutsaers, J. E. Bishop, G. McGrouther, and G. J. Laurent, “Mechanisms of tissue repair: from wound healing to fibrosis,” *The International Journal of Biochemistry & Cell Biology*, vol. 29, no. 1, pp. 5–17, 1997.
- [151] A. W. Joe, L. Yi, A. Natarajan et al., “Muscle injury activates resident fibro/adipogenic progenitors that facilitate myogenesis,” *Nature Cell Biology*, vol. 12, no. 2, pp. 153–163, 2010.
- [152] M. D. Grounds, “Complexity of extracellular matrix and skeletal muscle regeneration,” in *Skeletal Muscle Repair and Regeneration*, S. Schiaffino and T. Partridge, Eds., Advances in Muscle Research, pp. 269–301, Springer, Amsterdam, The Netherlands, 2008.
- [153] C. J. Mann, E. Perdiguero, Y. Kharraz et al., “Aberrant repair and fibrosis development in skeletal muscle,” *Skeletal Muscle*, vol. 1, no. 1, article 21, 2011.
- [154] G. Lluri, G. D. Langlois, B. McClellan, P. D. Soloway, and D. M. Jaworski, “Tissue inhibitor of metalloproteinase-2 (TIMP-2) regulates neuromuscular junction development via a beta1 integrin-mediated mechanism,” *Journal of Neurobiology*, vol. 66, no. 12, pp. 1365–1377, 2006.
- [155] Y. Li, W. Foster, B. M. Deasy et al., “Transforming growth factor- β 1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: a key event in muscle fibrogenesis,” *The American Journal of Pathology*, vol. 164, no. 3, pp. 1007–1019, 2004.
- [156] P. E. Mozdziak, P. M. Pulvermacher, and E. Schultz, “Muscle regeneration during hindlimb unloading results in a reduction in muscle size after reloading,” *Journal of Applied Physiology*, vol. 91, no. 1, pp. 183–190, 2001.
- [157] P. O. Mitchell and G. K. Pavlath, “Skeletal muscle atrophy leads to loss and dysfunction of muscle precursor cells,” *American Journal of Physiology: Cell Physiology*, vol. 287, no. 6, pp. C1753–C1762, 2004.
- [158] C. R. Slater and S. Schiaffino, “Skeletal muscle repair and regeneration,” in *Advances in Muscle Research*, S. Schiaffino and T. Partridge, Eds., pp. 303–334, Springer, Amsterdam, The Netherlands, 2008.
- [159] S. Sartore, L. Gorza, and S. Schiaffino, “Fetal myosin heavy chains in regenerating muscle,” *Nature*, vol. 298, no. 5871, pp. 294–296, 1982.
- [160] R. G. Whalen, J. B. Harris, G. S. Butler-Browne, and S. Sesodia, “Expression of myosin isoforms during notexin-induced regeneration of rat soleus muscles,” *Developmental Biology*, vol. 141, no. 1, pp. 24–40, 1990.
- [161] K. Esser, P. Gunning, and E. Hardeman, “Nerve-dependent and -independent patterns of mRNA expression in regenerating skeletal muscle,” *Developmental Biology*, vol. 159, no. 1, pp. 173–183, 1993.
- [162] M. Vinciguerra, A. Musaro, and N. Rosenthal, “Regulation of muscle atrophy in aging and disease,” *Advances in Experimental Medicine and Biology*, vol. 694, pp. 211–233, 2010.
- [163] B. M. Scicchitano, E. Rizzuto, and A. Musarò, “Counteracting muscle wasting in aging and neuromuscular diseases: the critical role of IGF-1,” *Aging*, vol. 1, no. 5, pp. 451–457, 2009.
- [164] S. Carosio, M. G. Berardinelli, M. Aucello, and A. Musarò, “Impact of ageing on muscle cell regeneration,” *Ageing Research Reviews*, vol. 10, no. 1, pp. 35–42, 2011.
- [165] A. L. Serrano, C. J. Mann, B. Vidal, E. Arditte, E. Perdiguero, and P. Muñoz-Cánoves, “Cellular and molecular mechanisms regulating fibrosis in skeletal muscle repair and disease,” *Current Topics in Developmental Biology*, vol. 96, pp. 167–201, 2011.
- [166] B. M. Carlson and J. A. Faulkner, “Muscle transplantation between young and old rats: age of host determines recovery,” *The American Journal of Physiology: Cell Physiology*, vol. 256, no. 6, pp. C1262–C1266, 1989.
- [167] B. M. Carlson, E. I. Dedkov, A. B. Borisov, and J. A. Faulkner, “Skeletal muscle regeneration in very old rats,” *Journals of Gerontology A Biological Sciences and Medical Sciences*, vol. 56, no. 5, pp. B224–B233, 2001.
- [168] I. M. Conboy, M. J. Conboy, A. J. Wagers, E. R. Girma, I. L. Weismann, and T. A. Rando, “Rejuvenation of aged progenitor cells by exposure to a young systemic environment,” *Nature*, vol. 433, no. 7027, pp. 760–764, 2005.
- [169] M. Le Bihan, A. Bigot, S. S. Jensen et al., “In-depth analysis of the secretome identifies three major independent secretory pathways in differentiating human myoblasts,” *Journal of Proteomics*, vol. 77, pp. 344–356, 2012.
- [170] M. Bencze, E. Negroni, D. Vallese et al., “Proinflammatory macrophages enhance the regenerative capacity of human

- myoblasts by modifying their kinetics of proliferation and differentiation,” *Molecular Therapy*, vol. 20, no. 11, pp. 2168–2179, 2012.
- [171] L. Barberi, B. M. Scicchitano, M. De Rossi et al., “Age-dependent alteration in muscle regeneration: the critical role of tissue niche,” *Biogerontology*, vol. 14, no. 3, pp. 273–292, 2013.
- [172] P. Paliwal, N. Pishesha, D. Wijaya, and I. M. Conboy, “Age dependent increase in the levels of osteopontin inhibits skeletal muscle regeneration,” *Aging*, vol. 4, no. 8, pp. 553–566, 2012.
- [173] A. Hirata, S. Masuda, T. Tamura et al., “Expression profiling of cytokines and related genes in regenerating skeletal muscle after cardiotoxin injection: a role for osteopontin,” *The American Journal of Pathology*, vol. 163, no. 1, pp. 203–215, 2003.
- [174] K. Uaesoontrachoon, H. Yoo, E. M. Tudor, R. N. Pike, E. J. Mackie, and C. N. Pagel, “Osteopontin and skeletal muscle myoblasts: association with muscle regeneration and regulation of myoblast function in vitro,” *International Journal of Biochemistry and Cell Biology*, vol. 40, no. 10, pp. 2303–2314, 2008.
- [175] S. A. Vetrone, E. Montecino-Rodriguez, E. Kudryashova et al., “Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF- β ,” *Journal of Clinical Investigation*, vol. 119, no. 6, pp. 1583–1594, 2009.
- [176] E. R. Barton, L. Morris, A. Musaro, N. Rosenthal, and H. Lee Sweeney, “Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice,” *Journal of Cell Biology*, vol. 157, no. 1, pp. 137–147, 2002.
- [177] M. Wehling, M. J. Spencer, and J. G. Tidball, “A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice,” *Journal of Cell Biology*, vol. 155, no. 1, pp. 123–131, 2001.
- [178] S. A. Villalta, C. Rinaldi, B. Deng, G. Liu, B. Fedor, and J. G. Tidball, “Interleukin-10 reduces the pathology of mdx muscular dystrophy by deactivating M1 macrophages and modulating macrophage phenotype,” *Human Molecular Genetics*, vol. 20, no. 4, pp. 790–805, 2011.
- [179] P. Sousa-Victor, S. Gutarra, L. García-Prat et al., “Geriatric muscle stem cells switch reversible quiescence into senescence,” *Nature*, vol. 506, pp. 316–321, 2014.
- [180] B. D. Cosgrove, P. M. Gilbert, E. Porpiglia et al., “Rejuvenation of the muscle stem cell population restores strength to injured aged muscles,” *Nature Medicine*, vol. 20, pp. 255–264, 2014.
- [181] M. Li and J. C. Izpisua Belmonte, “Ageing: genetic rejuvenation of old muscle,” *Nature*, vol. 506, pp. 304–305, 2014.
- [182] M. A. Rudnicki, T. Braun, S. Hinuma, and R. Jaenisch, “Inactivation of MyoD in mice leads to up-regulation of the myogenic HLH gene Myf-5 and results in apparently normal muscle development,” *Cell*, vol. 71, no. 3, pp. 383–390, 1992.
- [183] L. A. Sabourin, A. Girgis-Gabardo, P. Scale, A. Asakura, and M. A. Rudnicki, “Reduced differentiation potential of primary MyoD^{-/-} myogenic cells derived from adult skeletal muscle,” *Journal of Cell Biology*, vol. 144, no. 4, pp. 631–643, 1999.
- [184] D. D. Cornelison, B. B. Olwin, M. A. Rudnicki, and B. J. Wold, “MyoD^{-/-} satellite cells in single-fiber culture are differentiation defective and MRF4 deficient,” *Developmental Biology*, vol. 224, no. 2, pp. 122–137, 2000.
- [185] T. Braun, M. A. Rudnicki, H.-. Arnold, and R. Jaenisch, “Targeted inactivation of the muscle regulatory gene Myf-5 results in abnormal rib development and perinatal death,” *Cell*, vol. 71, no. 3, pp. 369–382, 1992.
- [186] S. Tajbakhsh, D. Rocancourt, G. Cossu, and M. Buckingham, “Redefining the genetic hierarchies controlling skeletal myogenesis: pax-3 and Myf-5 act upstream of MyoD,” *Cell*, vol. 89, no. 1, pp. 127–138, 1997.
- [187] A. Kaul, M. Köster, H. Neuhaus, and T. Braun, “Myf-5 revisited: loss of early myotome formation does not lead to a rib phenotype in homozygous Myf-5 mutant mice,” *Cell*, vol. 102, no. 1, pp. 17–19, 2000.
- [188] J. M. Venuti, J. H. Morris, J. L. Vivian, E. N. Olson, and W. H. Klein, “Myogenin is required for late but not early aspects of myogenesis during mouse development,” *Journal of Cell Biology*, vol. 128, no. 4, pp. 563–576, 1995.
- [189] J. R. Knapp, J. K. Davie, A. Myer, E. Meadows, E. N. Olson, and W. H. Klein, “Loss of myogenin in postnatal life leads to normal skeletal muscle but reduced body size,” *Development*, vol. 133, no. 4, pp. 601–610, 2006.
- [190] J. L. Vivian, E. N. Olson, and W. H. Klein, “Thoracic skeletal defects in myogenin- and MRF4-deficient mice correlate with early defects in myotome and intercostal musculature,” *Developmental Biology*, vol. 224, no. 1, pp. 29–41, 2000.
- [191] A. L. Thompson, G. Filatov, C. Chen et al., “A selective role for MRF4 innervated adult skeletal muscle: Na(V) 1.4 Na⁺ channel expression is reduced in MRF4-null mice,” *Gene Expression*, vol. 12, pp. 289–303, 2005.



Hindawi

Submit your manuscripts at
<http://www.hindawi.com>

